Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression phenotype BEFREE The sequence of mutations in the process of lymphomagenesis seems to be composed of at least 3 main hits which equip the cells with independence from external mitogenic signals (activation of Ras/Raf), resistance to inducers of apoptosis (activation of Bcl-2) and generation of cellular heterogeneity (deletion of p53) important in tumor progression. 10722231 2000
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker phenotype BEFREE These results indicate that Bcl-2 inhibits tumor progression in the liver, possibly by interfering with hepatocyte proliferation. 11212255 2001
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression phenotype BEFREE Although cytoplasmic bcl-2 overexpression is found in the majority of tumours in the younger group, it is not associated with tumour progression and recurrence. 11464113 2001
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker phenotype BEFREE Thus, acquisition of Bcl-2 expression is as advantageous for tumor cell growth in vivo as is p53 inactivation but does not affect genomic stability and creates the environment restrictive for the expansion of genetically unstable and potentially malignant p53-deficient cells, causing a delay in tumor progression and explaining the different prognostic value of Bcl-2 and p53. 12170763 2002
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker phenotype BEFREE Overexpression of the anti-apoptotic proteins bcl-2 and bcl-xL is implicated in breast cancer development, tumor progression and drug resistance. 12452453 2002
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker phenotype BEFREE Bcl-2 and Bcl-X(L) may play a critical role in cancer progression. 14613034 2003
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression phenotype BEFREE Loss of Bcl-2 expression in Barrett's dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation. 12581249 2003
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker phenotype BEFREE Previous studies further suggest that such phospho-Bcl-2 regulation may influence tumor progression in colorectal and other cancers; however, phosphorylation status of the Ser70 of Bcl-2 (pSer70) in vivo in tumors remains obscure. 16243795 2005
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression phenotype BEFREE It is also suggested that the effect of alteration of bcl-2 expression might be minimal during the tumor progression stage because of the reduced expression in tumors of the clear cell type, which is the most dominant cell type in RCC. 16643620 2006
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker phenotype BEFREE To determine whether a specifically designed bispecific (Bcl-2/Bcl-xL) antisense oligonucleotide (ASO) induces apoptosis and enhances chemosensitivity in human prostate cancer LNCaP cells, as Bcl-2 and Bcl-xL are both anti-apoptotic genes associated with treatment resistance and tumour progression in many malignancies, including prostate cancer. 16686729 2006
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression phenotype BEFREE Expression of the proto-oncogene Bcl-2 is associated with tumor progression. 17237270 2007
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression phenotype BEFREE The knockdown of XIAP, BCL2 and BCL-X(L) by siRNAs represents a promising treatment option for bladder cancer (BCa) since the overexpression of antiapoptotic genes is often associated with tumor progression and treatment resistance. 18751404 2008
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker phenotype BEFREE These data indicate that the survival requirements for tumor-susceptible PC(pre) and PCs are distinct and that tumor progression likely develops as PC(pre) transition to functional PCs when apoptotic pathways such as members of the Bcl-2 family are disabled. 19017943 2008
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker phenotype BEFREE Bcl-2 is a prime target for novel therapeutics because it is elevated in many forms of cancer and contributes to cancer progression and therapy resistance based on its ability to inhibit apoptosis. 19056433 2009
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression phenotype BEFREE Our results further revealed that NRP-1 knockdown decreased the expression levels of Bcl-2 family proteins and deactivated extracellular signal-regulated kinase (ERK) and c-Jun-N-terminal kinase (JNK)/mitogen-activated protein kinase (MAPK) signaling pathways, closely associated with cancer progression. 21842123 2012
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression phenotype BEFREE BCL2 expression in CD105 positive neoangiogenic cells and tumor progression in angioimmunoblastic T-cell lymphoma. 22322190 2012
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression phenotype BEFREE Deregulation of apoptosis is one of the important features of AML and to understand the molecular mechanism underlying apoptosis and its contribution to tumor progression, this study aimed to evaluate anti-apoptotic Bcl2 protein expression in AML and correlate with FLT3 parameters for their role in prognosis of disease.Bcl2 and FLT3 protein expression was quantified by flow cytometry on leukemic blasts in total 174 de novo AML, myelodysplastic syndrome (MDS) and aplastic anemia patients. 23906301 2013
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression phenotype BEFREE Furthermore, the expression of integrins and Bcl-2 in LCs had a tendency to correlate with the clinical stage of cancer progression, including lymph node metastasis. 23108890 2013
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression phenotype BEFREE These findings indicate the role of miR-34a in tumor progression may be closely associated with p53 mutation and inversely correlated to Bcl-2 expression. 23529798 2013
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression phenotype BEFREE With long-term I2, mammary tumor tissue became more sensitive to DOX, since a single injection of the lowest dose of DOX (4 mg/Kg) was enough to stop tumor progression and a second DOX4 injection on day 14 caused a significant and rapid decrease in tumor size, decreased the expression of chemoresistance markers (Bcl2 and survivin), and increased the expression of the apoptotic protein Bax and peroxisome proliferator-activated receptor type gamma. 23705792 2013
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker phenotype BEFREE No significant risk for developing tumor progression was associated with Ki-67, p53, Bax, Bcl-2, VEGFR-1, VEGFR-2, or VEGF-A expression. 25109698 2014
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression phenotype BEFREE In SCRT, long break in the treatment should be avoided because correlation between Ki-67, KU70, and BCL-2 expressions and pTNM after RT might indicate tumor progression. 24756926 2014
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker phenotype BEFREE Moreover, the enhanced expression and/or activities of some drug resistance-associated molecules such as Bcl-2, Akt/molecular target of rapamycin (mTOR), nuclear factor-kappaB (NF-κB), hypoxia-inducible factors (HIFs), macrophage inhibitory cytokine-1 (MIC-1) and ATP-binding cassette (ABC) multidrug transporters frequently occur in cancer cells during cancer progression and metastases. 23994756 2014
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker phenotype BEFREE Mechanistic investigations reveal that a miR-197-mediated CKS1B/STAT3 axis exerts tumor progression regulated by various oncogenic genes (Bcl-2, c-Myc, and cyclin D1), and PD-L1 is a putative biomarker of this axis. 25597412 2015
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker phenotype BEFREE Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment. 25827952 2015